Funding for this research was provided by:
Ministry of Health and Welfare
Article History
Received: 16 February 2022
Accepted: 24 April 2022
First Online: 23 May 2022
Declarations
:
: The authors of this manuscript have the following competing interests: RN received honoraria from Sanofi Co., Ltd., Japan Medtronic Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Takeda Pharmaceutical Company Limited, Kissei Pharmaceutical Co., Ltd., Novartis Pharma Co., Ltd., Eli Lilly Japan Co., Ltd., Novo Nordisk Pharma Ltd., MSD and Astellas Pharma Inc, and subsidies or donations from Taisho Pharmaceutical Co., Ltd, Ono Pharmaceutical Co., Ltd, Takeda Pharmaceutical Company Limited and Nippon Boehringer Ingelheim Co., Ltd. TH received honoraria from Eli Lilly Japan Co., Ltd. YS have no conflicts of interest to declare.
: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (the Ethics Committee of the Jikei University School of Medicine (approval number 27–091(7976), approved September 7, 2015) and with the Helsinki Declaration of 1964 and its later versions.
: Written informed consent was obtained from all patients.